Google Glass pulled from consumer market, but still available for medical purposes; Insulin pump maker plans IPO;

@FierceMedDev: ICYMI: Profit down 12% at Intuitive Surgical, but procedure volume up due to strength abroad and in general surgery. Report | Follow @FierceMedDev

@VarunSaxena2: GE Healthcare says strong U.S. growth offset weakness abroad. Story | Follow @VarunSaxena2

@EmilyWFierce: Obama and Narendra Modi scheduled to meet with top U.S. and Indian execs today to discuss business barriers. Story from the WSJ (sub. req.) | Follow @EmilyWFierce

> The Google Glass Explorer Edition is no longer available to consumers. Many are writing off the product as a failure, but Augmedix, which is using the tool to help physicians manage electronic health records, says it isn't affected by the decision and will continue to have access to the product. Google ($GOOG) says future versions of Google Glass are in the works. Google's release | Story

> Insulin pump maker Asante Solutions hopes to raise $49 million by offering 3.5 million shares for between $13 and $15 in its upcoming IPO. Story

> Mainstay Medical has applied with the FDA to begin clinical trials of its Reactiv8 neurostimulation device for chronic lower back pain. Release

> Most medical device exits occur 8 to 10 years after inception. Only one in three occur at the prerevenue stage. Those companies sold after 9 years will need more than $50 million in funding. More

Biotech News

@FierceBiotech: Sanofi, Regeneron capture a shot at first-mover advantage in the PCSK9 market. Report | Follow @FierceBiotech

@JohnCFierce: Rockwell's dialysis drug wins an FDA OK, despite lingering doubts. Article | Follow @JohnCFierce

@DamianFierce: Under-rated aspect of $GILD's hep C dominance: correctly spelling "hepatology." More | Follow @DamianFierce

> Novartis hands off another PhIII drug to Array. News

> Pfizer has $33B and the M&A world at its feet. More

> FDA approves NPS Pharma's drug, burnishing Shire's $5.2B bet. Report

Pharma News

@FiercePharma: Harvard engineer taps immunotherapy for insights into nonsurgical pet sterilization. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Actavis explains the recall of generic Neurontin was limited to 2,000 bottles shipped to one customer. FiercePharmaManufacturing story | Follow @EricPFierce

> Novo Nordisk puts 500 Saxenda reps on U.S. streets, aiming for $1B in weight-loss sales. More

> Gilead discounts hep C meds in Germany, offers new-and-improved generics deal in India. News

Biotech IT News

> EMA posts guide to help IT teams with its new pharmacovigilance database. News

> Obama talks up precision meds, cybersecurity in SOTU speech. More

> $4B VC shop lays out its vision for the future of digital health. Story

> GoBalto eyes Asian expansion after $12M Mitsui-led financing. Report

> BIO is preparing small biotechs for life in the social media maelstrom. Article

CRO News

> Trial tech outfit goBalto bags $12M to expand around the world. Report

> PPD beefs up its Irish outpost with a new biologics lab. News

> Australian CRO Novotech firms up its Hong Kong presence. More

> EMA wants more than 700 drugs suspended over GVK data scandal. Story

> Covance pools its early-stage R&D services into one offering. Article

Animal Health News

> Report: Merck said to be testing lower dosage Zilmax to revive sales. More

> Bayer study reveals growth opportunity for vet clinics in fighting parasites. Item

> Valeant CEO quashes rumors of Zoetis buyout bid. Article

> Harvard engineer taps immunotherapy for insights into nonsurgical pet sterilization. Story

> Report: Livestock research lab prioritizes profits over animal health. More

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.